Analysis of the TCGA database revealed that high ESRP1 expression is significantly associated with shorter progression-free survival and that ESRP1 overexpression drives MET in association with the upregulation of CDH1 expression and alternative splicing of CD44 and ENAH, but not FGFR2, in ovarian cancer cells [13]. Here, ESRP1 is linked to ovarian cancer.